Another study links rituximab to increased risk of COVID-19 death

Other immune-modifying therapies don't confer a similar risk, according to findings from a huge database analysis

Rituximab is an outlier among targeted immune-modifying rheumatological therapies as it alone is associated with an increased risk of death in patients who develop COVID-19, a new study shows.

The UK cohort study of more than 17 million patients has found use of rituximab for immune-mediated inflammatory diseases is linked to a 68% increased risk of death compared with standard systemic therapy.

The findings also link the monoclonal antibody — as well as drugs in the Janus kinase

Latest